HKBU collaborates with Mainland pharmaceutical company to establish joint innovative research platform for Chinese medicines
22 Apr 2015
HKBU signed an agreement with Zhangzhou Pien Tze Huang Pharmaceutical Company Limited today (22 April) to establish a joint innovative research platform for Chinese medicines. By integrating their technologies and cooperation network, the two parties aim to conduct innovative research on Chinese medicines. Together, they plan to build a modern, multi-disciplinary centre for innovative research into Chinese medicines with wide application prospects that meet international advanced standards. The centre will also serve as a think tank for the two parties in the research and development of new drugs and health products, such as health food products.
The Company plans to provide research funding of HK$5 million, while the School of Chinese Medicine will contribute knowledge and technologies. The two parties will join hands to conduct innovative research on Chinese medicines, submit joint applications for government research grants and provide researchers with secondment opportunities. Planned collaborations include the study on proprietary Chinese medicines including the “Pien Tze Huang” treatment for chronic inflammatory conditions, development of health food products, and studies into the efficacy, composition, preparation and mechanism of other products of the Company with a view to developing new and improved drugs.
Professor Albert Chan, President and Vice-Chancellor, said Zhangzhou Pien Tze Huang is a leading pharmaceutical enterprise in Mainland China whose products are held in high regard both at home and overseas, and the School of Chinese Medicine has built up considerable strength in discovering new Chinese herbal drugs. As a result, the collaboration will enhance the strengths of the two parties and benefit the Chinese medicines industry in the region as well as public health.